Plant disease control composition and method for controlling plant disease by application of same

Abstract

Provided is a plant disease control composition that has a plurality of disease spectra against various plant pathogens and demonstrates superior control effects (synergistic control effects) that cannot be predicted from each component alone. The plant disease control composition comprises as active ingredients thereof at least one quinoline compounds represented by the following general formula: ##STR00001##
wherein, R.sup.1 and R.sup.2 represent, for example, optionally substituted alkyl groups or optionally substituted aryl groups, R.sup.3 and R.sup.4 represent, for example, hydrogen atoms, fluorine atom or methyl group, X represents, for example, a halogen atom or optionally substituted alkyl group, and Y represents a fluorine atom or methyl group, n is 0 to 2 and m is 0 or 1, or a salt thereof (group a), and one or more fungicidal compounds selected from group b.

Claims

1. A plant disease control composition comprising as active ingredients thereof: (a) at least one quinoline compound selected from the group consisting of (a-14) 3-(5-fluoro-3,3,4,4-tetramethyl-3,4-dihydroisoquinolin-1-yl)quinoline, (a-18) 3-(4,4-difluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, and (a-20) 3-(4,4,5-trifluoro-3,3-dimethyl-3,4-dihydroisoquinolin-1-yl)quinoline, or a salt thereof (group a); and (b) one or more fungicidal compounds selected from (group b): pyrazole carboxamides consisting of (b-2) Benzovindiflupyr, and (b-3) a compound of formula (II) ##STR00093## azole compounds consisting of (b-36) compounds of general formula (V) ##STR00094## wherein Rb.sub.7 represents a hydrogen atom, alkyl group, allyl group, benzyl group, amino group, cyano group or a valency that forms a double bond between a sulfur atom and a triazole ring to generate a ring represented by: ##STR00095## and Rb.sub.8 represents a hydrogen atom or fluorine atom, and and (b-38) compounds of general formula (VII) ##STR00096## wherein Rb.sub.10 represents a halogen atom and Rb.sub.11 represents a nitrogen atom or methine group; amide compounds consisting of (b-47) Isofetamid, (b-48) Valifenalate, and (b-49) Pyraziflumid, ##STR00097## a strobilurin compound consisting of (b-56) Mandestrobin; an aminopyridine compound consisting of (b-78) Picarbutrazox; other fungicidal compounds (i) consisting of (b-84) Oxathiapiprolin, (b-85) compounds of general formula (XI) ##STR00098## wherein Rb.sub.1 represents a chlorine atom, bromine atom, cyano group, methyl group or methoxy group, Rb.sub.2 represents a fluorine atom or hydrogen atom, Rb.sub.3 represents a halogen atom, Rb.sub.4 represents a halogen atom, methoxy group or hydrogen atom and Z represents N or CF, (b-88) a compound of formula (XIV) ##STR00099## (b-89) compounds of general formula (XV) ##STR00100## wherein Rb.sub.13 represents a chlorine atom or fluorine atom, Rb.sub.14 represents a chlorine atom or hydrogen atom and Rb.sub.15 represents a chlorine atom or bromine atom; other fungicidal compounds (ii) consisting of (b-91) a compound of formula (XVII) ##STR00101## (b-92) a compound of formula (XVIII) ##STR00102## (b-93) D-tagatose, and (b-94) compounds of general formula (XIX) ##STR00103## wherein Rb.sub.17 represents a hydrogen atom or fluorine atom.

2. A method for controlling plant disease, comprising applying the plant disease control composition according to claim 1.

3. A method for controlling plant disease, comprising simultaneously applying a plant disease control composition containing a quinoline compound of group a as an active ingredient thereof and a plant disease control composition containing a fungicidal compound of group b as an active ingredient thereof, or applying one of either a plant disease control composition containing a quinoline compound of group a as an active ingredient thereof or a plant disease control composition containing a fungicidal compound of group b as an active ingredient thereof, followed by applying the other composition, wherein each of the plant disease compositions is in accordance with claim 1.

Description

EXAMPLES

(1) The following provides a more detailed explanation of the present invention by listing preparation examples and test examples thereof. However, the present invention is not limited to only these preparation examples and test examples. Furthermore, the number of parts of all incorporated amounts of each component described in the following preparation examples refers to parts by weight.

(2) Compound A (a-14), B (a-18) and C (a-20) among the compounds (I: group a) used in the following preparation examples and test examples respectively refer to Compound Nos. 1-866, 1-929 and 1-930 of International Publication No. WO 2005/070917, and are respectively described therein in Examples 114, 177 and 178. The chemical structures thereof are shown in Table 1.

(3) TABLE-US-00001 TABLE 1 Compound R.sup.1 R.sup.2 R.sup.3 R.sup.4 Xn Ym A(a-14) Me Me Me Me 5-F H B(a-18) Me Me F F H H C(a-20) Me Me F F 5-F H

(4) In addition, the fungicidal compound of formula (VII)-1 of compound (b-38) used in the following preparation examples and test examples is a compound represented by the following formula.

(5) ##STR00092##

Preparation Example 1 Wettable Powder (WP) (a1)

(6) Component I (group a) in the form of any of Compounds A, B and C (10, 1 or 0.01 parts), Component II (group b) in the form of any of the compounds described below (added amount indicated), Neogen powder (0.5 parts), Carplex (0.5 parts), Gohsenol (0.2 parts), Radiolite (0.8 parts) and H fine powder (used as the balance to bring to a total of 100 parts) were crushed and mixed to obtain wettable powder (a1).

(7) The compounds (added amounts) used for Component II (group b) consisted of (b-1) (2 parts), (b-2) (2 parts), (b-3) (2 parts), (b-4) (2 to 10 parts), (b-5) (2 to 50 parts), (b-6) (0.4 to 50 parts), (b-7) (0.4 to 50 parts), (b-8) (0.4 to 2 parts), (b-9) (0.4 to 2 parts), (b-16) (2 parts), (b-19) (2 parts), (b-20) (0.4 to 10 parts), (b-21) (0.4 to 10 parts), (b-22) (0.4 to 10 parts), (b-23) (2 to 10 parts), (b-24) (0.4 to 10 parts), (b-25) (0.4 to 10 parts), (b-26) (0.4 to 10 parts), (b-27) (0.4 to 10 parts), (b-28) (0.4 to 10 parts), (b-29) (0.4 to 10 parts), (b-30) (0.4 to 10 parts), (b-31) (0.4 to 10 parts), (b-32) (0.4 to 10 parts), (b-33) (25 to 50 parts), (b-34) (0.4 to 10 parts), (b-35) (0.4 to 10 parts), (b-36) (0.4 to 10 parts), (b-38) (2 parts), (b-39) (0.4 parts), (b-40) (2 parts), (b-41) (50 parts), (b-42) (50 parts), (b-43) (2 to 10 parts), (b-44) (0.08 parts), (b-45) (10 parts), (b-46) (2 to 10 parts), (b-47) (10 parts), (b-49) (2 parts), (b-50) (2 parts), (b-51) (2 to 50 parts), (b-52) (2 to 50 parts), (b-53) (2 to 50 parts), (b-54) (2 parts), (b-55) (2 to 10 parts), (b-58) (10 to 50 parts), (b-59) (2 parts), (b-60) (10 to 50 parts), (b-61) (10 to 50 parts), (b-62) (10 to 50 parts), (b-63) (0.016 to 50 parts), (b-64) (10 parts), (b-65) (0.4 to 50 parts), (b-66) (0.4 to 50 parts), (b-67) (50 parts), (b-68) (50 parts), (b-69) (50 parts), (b-70) (50 parts), (b-71) (10 to 50 parts), (b-72) (2 to 10 parts), (b-73) (10 parts), (b-74) (0.4 to 50 parts), (b-75) (2 parts), (b-76) (25 parts), (b-77) (0.016 to 50 parts), (b-78) (0.4 parts), (b-81) (2 to 50 parts), (b-82) (0.08 to 50 parts), (b-83) (0.08 to 10 parts), (b-84) (0.0016 to 50 parts), (b-85) (10 parts), (b-88) (2 parts), (b-89) (2 parts), (b-91) (0.08 to 2 parts), (b-92) (0.4 parts), (b-93) (50 parts), (b-94) (0.4 to 10 parts), (b-95) (2 parts), (b-96) (10 to 50 parts), (b-97) (0.08 parts), (b-98) (2 parts), (b-99) (10 to 50 parts), (b-100) (0.016 to 50 parts), (b-101) (0.4 to 50 parts), (b-102) (0.4 to 50 parts), (b-103) (10 to 50 parts), (b-104) (50 parts), (b-105) (25 to 50 parts), (b-106) (25 parts).

Preparation Example 2 Suspension Concentrate (SC) (b1)

(8) Component I (group a) in the form of any of Compounds A, B and C (10 or 1 parts), Component II (group b) in the form of any of the compounds described below (added amount indicated), propylene glycol (7 parts), sodium lignin sulfonate (4 parts), sodium dioctylsulfosuccinate (2 parts) and water (used as the balance to bring to a total of 100 parts) were wet-crushed with a sand grinder to obtain suspension concentrate (b1).

(9) The compounds (added amounts) used for Component II (group b) consisted of (b-1) (2 parts), (b-2) (2 parts), (b-3) (2 parts), (b-4) (2 to 10 parts), (b-5) (2 to 50 parts), (b-6) (0.4 to 50 parts), (b-7) (0.4 to 50 parts), (b-8) (0.4 to 2 parts), (b-9) (0.4 to 2 parts), (b-16) (2 parts), (b-19) (2 parts), (b-20) (0.4 to 10 parts), (b-21) (0.4 to 10 parts), (b-22) (0.4 to 10 parts), (b-23) (2 to 10 parts), (b-24) (0.4 to 10 parts), (b-25) (0.4 to 10 parts), (b-26) (0.4 to 10 parts), (b-27) (0.4 to 10 parts), (b-28) (0.4 to 10 parts), (b-29) (0.4 to 10 parts), (b-30) (0.4 to 10 parts), (b-31) (0.4 to 10 parts), (b-32) (0.4 to 10 parts), (b-33) (25 to 50 parts), (b-34) (0.4 to 10 parts), (b-35) (0.4 to 10 parts), (b-36) (0.4 to 10 parts), (b-38) (2 parts), (b-39) (0.4 parts), (b-40) (2 parts), (b-41) (50 parts), (b-42) (50 parts), (b-43) (2 to 10 parts), (b-44) (0.08 parts), (b-45) (10 parts), (b-46) (2 to 10 parts), (b-47) (10 parts), (b-49) (2 parts), (b-50) (2 parts), (b-51) (2 to 50 parts), (b-52) (2 to 50 parts), (b-53) (2 to 50 parts), (b-54) (2 parts), (b-55) (2 to 10 parts), (b-58) (10 to 50 parts), (b-59) (2 parts), (b-60) (10 to 50 parts), (b-61) (10 to 50 parts), (b-62) (10 to 50 parts), (b-63) (0.016 to 50 parts), (b-64) (10 parts), (b-65) (0.4 to 50 parts), (b-66) (0.4 to 50 parts), (b-67) (50 parts), (b-68) (50 parts), (b-69) (50 parts), (b-70) (50 parts), (b-71) (10 to 50 parts), (b-72) (2 to 10 parts), (b-73) (10 parts), (b-74) (0.4 to 50 parts), (b-75) (2 parts), (b-76) (25 parts), (b-77) (0.016 to 50 parts), (b-78) (0.4 parts), (b-81) (2 to 50 parts), (b-82) (0.08 to 50 parts), (b-83) (0.08 to 10 parts), (b-84) (0.0016 to 50 parts), (b-85) (10 parts), (b-88) (2 parts), (b-89) (2 parts), (b-91) (0.08 to 2 parts), (b-92) (0.4 parts), (b-94) (0.4 to 10 parts), (b-95) (2 parts), (b-96) (10 to 50 parts), (b-97) (0.08 parts), (b-98) (2 parts), (b-99) (10 to 50 parts), (b-100) (0.016 to 50 parts), (b-101) (0.4 to 50 parts), (b-102) (0.4 to 50 parts), (b-103) (10 to 50 parts), (b-104) (50 parts), (b-105) (25 to 50 parts), (b-106) (25 parts).

Preparation Example 3 Emulsion Concentrate (EC) (c1)

(10) Component I (group a) in the form of any of Compounds A, B and C (10 or 1 parts), Component II (group b) in the form of any of the compounds described below (added amount indicated), cyclohexane (10 parts), Tween20 (surfactant, 20 parts) and xylene (used as the balance to bring to a total of 100 parts) were uniformly dissolved and mixed to obtain emulsion concentrate (c1).

(11) The compounds (added amounts) used for Component II (group b) consisted of (b-1) (2 parts), (b-2) (2 parts), (b-3) (2 parts), (b-4) (2 to 10 parts), (b-5) (2 to 50 parts), (b-6) (0.4 to 50 parts), (b-7) (0.4 to 50 parts), (b-8) (0.4 to 2 parts), (b-9) (0.4 to 2 parts), (b-16) (2 parts), (b-19) (2 parts), (b-20) (0.4 to 10 parts), (b-21) (0.4 to 10 parts), (b-22) (0.4 to 10 parts), (b-23) (2 to 10 parts), (b-24) (0.4 to 10 parts), (b-25) (0.4 to 10 parts), (b-26) (0.4 to 10 parts), (b-27) (0.4 to 10 parts), (b-28) (0.4 to 10 parts), (b-29) (0.4 to 10 parts), (b-30) (0.4 to 10 parts), (b-31) (0.4 to 10 parts), (b-32) (0.4 to 10 parts), (b-33) (25 to 50 parts), (b-34) (0.4 to 10 parts), (b-35) (0.4 to 10 parts), (b-36) (0.4 to 10 parts), (b-38) (2 parts), (b-39) (0.4 parts), (b-40) (2 parts), (b-41) (50 parts), (b-42) (50 parts), (b-43) (2 to 10 parts), (b-44) (0.08 parts), (b-45) (10 parts), (b-46) (2 to 10 parts), (b-47) (10 parts), (b-49) (2 parts), (b-50) (2 parts), (b-51) (2 to 50 parts), (b-52) (2 to 50 parts), (b-53) (2 to 50 parts), (b-54) (2 parts), (b-55) (2 to 10 parts), (b-58) (10 to 50 parts), (b-59) (2 parts), (b-60) (10 to 50 parts), (b-61) (10 to 50 parts), (b-62) (10 to 50 parts), (b-63) (0.016 to 50 parts), (b-64) (10 parts), (b-65) (0.4 to 50 parts), (b-66) (0.4 to 50 parts), (b-67) (50 parts), (b-68) (50 parts), (b-69) (50 parts), (b-70) (50 parts), (b-71) (10 to 50 parts), (b-72) (2 to 10 parts), (b-73) (10 parts), (b-74) (0.4 to 50 parts), (b-75) (2 parts), (b-76) (25 parts), (b-77) (0.016 to 50 parts), (b-78) (0.4 parts), (b-81) (2 to 50 parts), (b-82) (0.08 to 50 parts), (b-83) (0.08 to 10 parts), (b-84) (0.0016 to 50 parts), (b-85) (10 parts), (b-88) (2 parts), (b-89) (2 parts), (b-91) (0.08 to 2 parts), (b-92) (0.4 parts), (b-94) (0.4 to 10 parts), (b-95) (2 parts), (b-96) (10 to 50 parts), (b-97) (0.08 parts), (b-98) (2 parts), (b-99) (10 to 50 parts), (b-100) (0.016 to 50 parts), (b-101) (0.4 to 50 parts), (b-102) (0.4 to 50 parts), (b-103) (10 to 50 parts), (b-104) (50 parts), (b-105) (25 to 50 parts), (b-106) (25 parts).

Comparative Preparation Example 1 Wettable Powder (WP) (a2)

(12) Water-dispersible powder (a2) was obtained using the same method as Preparation Example 1 with the exception of containing only one of either Component I (group a) or Component II (group b).

Comparative Preparation Example 2 Suspension Concentrate (SC) (b2)

(13) Suspension concentrate preparation (b2) was obtained using the same method as Preparation Example 2 with the exception of containing only one of either Component I (group a) or Component II (group b).

Comparative Preparation Example 3 Emulsion Concentrate (EC) (c2)

(14) Emulsion (c2) was obtained using the same method as Preparation Example 3 with the exception of containing only one of either Component I (group a) or Component II (group b).

Comparative Preparation Example 4 Wettable Powder (WP) (a3)

(15) Water-dispersible powder (a3) was obtained using the same method as Preparation Example 1 with the exception of containing Component II (group b) compounds described below in place of those used for Wettable powder (WP) (a1). The compounds (added amounts) used for Component II (group b) consisted of Diclocymet (0.4 to 50 parts), Carpropamid (0.4 to 50 parts), Tolclofos-methyl (10 to 50 parts), and Oxolinic acid (50 parts).

Test Example 1 Tomato Gray Mold Preventive Test

(16) Tomato plants (variety: Ohgata Fukuju) planted in plastic pots having a diameter of 5 cm were grown indoors to the second to third leaf stage. Wettable powder prepared in compliance with Preparation Example 1 and Comparative Preparation Example 1 containing the compounds indicated in Table 2 were diluted with water to a prescribed concentration followed by spraying with a sprayer in 5 ml aliquots per 2 pots. After the chemical had dried, a conidia suspension of Botrytis cinerea which prepared from previously cultured in PDA medium was inoculated by spraying onto the plants. Following inoculation, the pots were placed in the humidified chamber of an artificial inoculation room (25? C.) and after 2 days, the pots were taken out and controlling effects were examined. During the examination, the percentage of affected area exhibiting lesions on a single tomato leaf was determined in accordance with the following incidence degree indicators. In addition, control values were calculated according to the equation indicated below from the average incidence degree of each treated group. The spray test results and theoretical values as determined according to Colby's formula are shown in Table 2.

(17) TABLE-US-00002 Incidence Degree Indicators Indicator Incidence Degree 0 No lesions 0.5 Lesion area of about 1% to 2% 1 Lesion area of less than 5% 2 Lesion area of less than 25% 3 Lesion area of less than 50% 4 Lesion area of less than 75% 5 Lesion area of less than 95% 6 Lesion area of 95% or more or withered

(18) Furthermore, the average values of each treated group and an untreated group were used for incidence degree.

(19) Control values were calculated from the equation indicated below.
Control value=(1?leaflet incidence rate of treated group/leaflet incidence rate of untreated group)?100

(20) Furthermore, synergistic effects were evaluated using Colby's formula. Colby's formula is expressed as X=P+Q?P?Q/100, where X represents the theoretical value of the control value, P represents the control value in the case of spraying a certain chemical agent alone, and Q represents the control value in the case of spraying the chemical agent used in combination alone. In the case the actual measured effect is greater than the effect X as calculated with the aforementioned Colby's formula, the action resulting from combining two types of active ingredients is indicated to be more than additive, that is, to be synergistic.

(21) TABLE-US-00003 TABLE 2-1 Treatment concen- Theo- Effective ingredient tration Control retical in the preparation (ppm) value value A + Compound of formula (II) (b-3) 10 + 2 93 64 A + Picarbutrazox (b-78) 10 + 0.4 86 64 A + Compound of formula (XIV) (b-88) 10 + 2 89 69 A + Compound of formula (VII)-1 (b-3 8) 10 + 2 82 67 B + Compound of formula (II) (b-3) 10 + 2 79 57 B + Picarbutrazox (b-78) 10 + 0.4 86 57 B + Compound of formula (XIV) (b-88) 10 + 2 79 63 B + Compound of formula (VII)-1 (b-38) 10 + 2 82 60 C + Compound of formula (II) (b-3) 10 + 2 79 57 C + Picarbutrazox (b-78) 10 + 0.4 75 57 C + Compound of formula (XIV) (b-88) 10 + 2 82 63 C + Compound of formula (VII)-1 (b-38) 10 + 2 82 60 Compound of formula (II) (b-3) 2 0 Picarbutrazox (b-78) 0.4 0 Compound of formula (XIV) (b-88) 2 14 Compound of formula (VII)-1 (b-38) 2 7 A 10 64 B 10 57 C 10 57

(22) TABLE-US-00004 TABLE 2-2 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Fluoxastrobin (b-51) 10 + 50 97 86 A + Dimoxystrobin (b-52) 10 + 50 97 81 A + Orysastrobin (b-53) 10 + 50 100 88 B + Fluoxastrobin (b-51) 10 + 50 100 86 B + Dimoxystrobin (b-52) 10 + 50 97 81 B + Orysastrobin (b-53) 10 + 50 100 88 C + Fluoxastrobin (b-51) 10 + 50 97 84 C + Dimoxystrobin (b-52) 10 + 50 97 78 C + Orysastrobin (b-53) 10 + 50 100 86 Fluoxastrobin (b-51) 50 40 Dimoxystrobin (b-52) 50 17 Orysastrobin (b-53) 50 47 A 10 77 B 10 77 C 10 73

(23) TABLE-US-00005 TABLE 2-3 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Carboxin (b-41) 10 + 50 97 75 A + Thifluzamide (b-42) 10 + 50 100 77 A + Isopyrazam (b-7) 10 + 50 100 82 A + Sedaxane (b-6) 10 + 50 97 85 A + Penflufen (b-5) 10 + 50 100 84 A + Cyprodinil (b-61) 10 + 50 97 85 A + Fenpyrazamine (b-99) 10 + 10 97 84 B + Carboxin (b-41) 10 + 50 97 75 B + Thifluzamide (b-42) 10 + 50 97 77 B + Isopyrazam (b-7) 10 + 50 97 82 B + Sedaxane (b-6) 10 + 50 100 85 B + Penflufen (b-5) 10 + 50 100 84 B + Cyprodinil (b-61) 10 + 50 100 85 B + Fenpyrazamine (b-99) 10 + 10 97 84 C + Carboxin (b-41) 10 + 50 100 67 C + Thifluzamide (b-42) 10 + 50 100 69 C + Isopyrazam (b-7) 10 + 50 97 76 C + Sedaxane (b-6) 10 + 50 100 80 C + Penflufen (b-5) 10 + 50 97 79 C + Cyprodinil (b-61) 10 + 50 97 80 C + Fenpyrazamine (b-99) 10 + 10 97 79 Carboxin (b-41) 50 17 Thifluzamide (b-42) 50 23 Isopyrazam (b-7) 50 40 Sedaxane (b-6) 50 50 Penflufen (b-5) 50 47 Cyprodinil (b-61) 50 50 Fenpyrazamine (b-99) 10 47 A 10 70 B 10 70 C 10 60

(24) TABLE-US-00006 TABLE 2-4 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Tetraconazole (b-22) 10 + 10 97 84 A + Epoxiconazole (b-24) 10 + 10 100 82 A + Ipconazole (b-25) 10 + 10 100 84 A + Metconazole (b-26) 10 + 10 97 84 A + Propiconazole (b-27) 10 + 10 100 82 A + Cyproconazole (b-28) 10 + 10 100 82 A + Difenoconazole (b-29) 10 + 10 97 84 A + Fluquinconazole (b-30) 10 + 10 100 84 A + Flusilazole (b-31) 10 + 10 100 82 A + Penconazole (b-32) 10 + 10 97 78 A + Flutriafol (b-34) 10 + 10 97 82 A + Myclobutanil (b-35) 10 + 10 100 82 A + Imazalil (b-20) 10 + 10 100 78 A + Prochloraz (b-21) 10 + 10 100 78 B + Tetraconazole (b-22) 10 + 10 100 84 B + Epoxiconazole (b-24) 10 + 10 100 82 B + Ipconazole (b-25) 10 + 10 97 84 B + Metconazole (b-26) 10 + 10 100 84 B + Propiconazole (b-27) 10 + 10 100 82 B + Cyproconazole (b-28) 10 + 10 100 78 B + Difenoconazole (b-29) 10 + 10 97 82 B + Fluquinconazole (b-30) 10 + 10 97 82 B + Flusilazole (b-31) 10 + 10 100 78 B + Penconazole (b-32) 10 + 10 100 78 B + Flutriafol (b-34) 10 + 10 100 82 B + Myclobutanil (b-35) 10 + 10 100 78 B + Imazalil (b-20) 10 + 10 97 78 B + Prochloraz (b-21) 10 + 10 100 78 C + Tetraconazole (b-22) 10 + 10 100 82 C + Epoxiconazole (b-24) 10 + 10 100 80 C + Ipconazole (b-25) 10 + 10 100 82 C + Metconazole (b-26) 10 + 10 100 82 C + Propiconazole (b-27) 10 + 10 97 80 C + Cyproconazole (b-28) 10 + 10 97 75 C + Difenoconazole (b-29) 10 + 10 97 80 C + Fluquinconazole (b-30) 10 + 10 100 80 C + Flusilazole (b-31) 10 + 10 97 75 C + Penconazole (b-32) 10 + 10 100 75 C + Flutriafol (b-34) 10 + 10 100 80 C + Myclobutanil (b-35) 10 + 10 100 75 C + Imazalil (b-20) 10 + 10 97 75 C + Prochloraz (b-21) 10 + 10 97 75 Tetraconazole (b-22) 10 40 Epoxiconazole (b-24) 10 33 Ipconazole (b-25) 10 40 Metconazole (b-26) 10 40 Propiconazole (b-27) 10 33 Cyproconazole (b-28) 10 17 Difenoconazole (b-29) 10 33 Fluquinconazole (b-30) 10 33 Flusilazole (b-31) 10 17 Penconazole (b-32) 10 17 Flutriafol (b-34) 10 33 Myclobutanil (b-35) 10 17 Imazalil (b-20) 10 17 Prochloraz (b-21) 10 17 A 10 73 B 10 73 C 10 70

(25) TABLE-US-00007 TABLE 2-5 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Thiabendazole (b-60) 10 + 50 100 87 A + Benomyl (b-58) 10 + 50 100 88 A + Thiuram (b-68) 10 + 50 100 90 A + Metiram (b-67) 10 + 50 100 90 A + Folpet (b-70) 10 + 50 100 92 A + Pyrisoxazole (b-103) 10 + 10 100 82 B + Thiabendazole (b-60) 10 + 50 100 87 B + Benomyl (b-58) 10 + 50 100 88 B + Thiuram (b-68) 10 + 50 100 90 B + Metiram (b-67) 10 + 50 100 90 B + Folpet (b-70) 10 + 50 100 92 B + Pyrisoxazole (b-103) 10 + 10 97 82 C + Thiabendazole (b-60) 10 + 50 100 87 C + Benomyl (b-58) 10 + 50 100 88 C + Thiuram (b-68) 10 + 50 100 90 C + Metiram (b-67) 10 + 50 100 90 C + Folpet (b-70) 10 + 50 100 92 C + Pyrisoxazole (b-103) 10 + 10 97 82 Thiabendazole (b-60) 50 57 Benomyl (b-58) 50 60 Thiuram (b-68) 50 67 Metiram (b-67) 50 67 Folpet (b-70) 50 73 Pyrisoxazole (b-103) 10 40 A 10 70 B 10 70 C 10 70

(26) TABLE-US-00008 TABLE 2-6 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Fenpropimorph (b-65) 10 + 50 97 78 A + Tridemorph (b-66) 10 + 50 100 78 A + Metrafenone (b-82) 10 + 50 100 73 A + Quinoxyfen (b-63) 10 + 50 100 78 A + Flutianil (b-77) 10 + 50 100 78 A + Proquinazid (b-100) 10 + 50 100 78 A + Spiroxamine (b-101) 10 + 50 100 78 A + Fenpropidin (b-102) 10 + 50 100 78 A + Sulfur (b-96) 10 + 50 100 73 A + Chinomethionat (b-74) 10 + 50 100 78 B + Fenpropimorph (b-65) 10 + 50 100 83 B + Tridemorph (b-66) 10 + 50 100 83 B + Metrafenone (b-82) 10 + 50 97 80 B + Quinoxyfen (b-63) 10 + 50 100 83 B + Flutianil (b-77) 10 + 50 100 83 B + Proquinazid (b-100) 10 + 50 100 83 B + Spiroxamine (b-101) 10 + 50 100 83 B + Fenpropidin (b-102) 10 + 50 100 83 B + Sulfur (b-96) 10 + 50 97 80 B + Chinomethionat (b-74) 10 + 50 100 83 C + Fenpropimorph (b-65) 10 + 50 100 81 C + Tridemorph (b-66) 10 + 50 100 81 C + Metrafenone (b-82) 10 + 50 100 77 C + Quinoxyfen (b-63) 10 + 50 100 81 C + Flutianil (b-77) 10 + 50 100 81 C + Proquinazid (b-100) 10 + 50 97 81 C + Spiroxamine (b-101) 10 + 50 100 81 C + Fenpropidin (b-102) 10 + 50 97 81 C + Sulfur (b-96) 10 + 50 100 77 C + Chinomethionat (b-74) 10 + 50 100 81 Fenpropimorph (b-65) 50 17 Tridemorph (b-66) 50 17 Metrafenone (b-82) 50 0 Quinoxyfen (b-63) 50 17 Flutianil (b-77) 50 17 Proquinazid (b-100) 50 17 Spiroxamine (b-101) 50 17 Fenpropidin (b-102) 50 17 Sulfur (b-96) 50 0 Chinomethionat (b-74) 50 17 A 10 73 B 10 80 C 10 77

(27) TABLE-US-00009 TABLE 2-7 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Trifloxystrobin (b-55) 10 + 10 100 78 A + Bixafen (b-4) 10 + 2 100 78 A + Fluopyram (b-43) 10 + 2 97 80 A + Prothioconazole (b-23) 10 + 2 97 78 A + Triadimenol (b-33) 10 + 50 97 72 A + Pyrimethanil (b-62) 10 + 10 97 78 A + Dithianon (b-81) 10 + 50 100 78 B + Trifloxystrobin (b-55) 10 + 10 97 78 B + Bixafen (b-4) 10 + 2 100 78 B + Fluopyram (b-43) 10 + 2 97 80 B + Prothioconazole (b-23) 10 + 2 100 78 B + Triadimenol (b-33) 10 + 50 100 72 B + Pyrimethanil (b-62) 10 + 10 100 78 B + Dithianon (b-81) 10 + 50 97 78 C + Trifloxystrobin (b-55) 10 + 10 100 78 C + Bixafen (b-4) 10 + 2 97 78 C + Fluopyram (b-43) 10 + 2 100 80 C + Prothioconazole (b-23) 10 + 2 97 78 C + Triadimenol (b-33) 10 + 50 100 72 C + Pyrimethanil (b-62) 10 + 10 100 78 C + Dithianon (b-81) 10 + 50 97 78 Trifloxystrobin (b-55) 10 33 Bixafen (b-4) 2 33 Fluopyram (b-43) 2 40 Prothioconazole (b-23) 2 33 Triadimenol (b-33) 50 17 Pyrimethanil (b-62) 10 33 Dithianon (b-81) 50 33 A 10 67 B 10 67 C 10 67

(28) TABLE-US-00010 TABLE 2-8 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Pyriofenone (b-83) 10 + 10 97 78 A + Compound of formula (XV)-1 (b-89) 10 + 2 100 80 A + Oxathiapiprolin (b-84) 10 + 50 97 78 A + Compound of formula (XIX) (b-94) 10 + 0.4 100 80 A + Compound of formula (XVII) (b-91) 10 + 2 100 80 A + Compound of formula (III) (b-8) 10 + 2 100 80 A + Compound of formula (IV) (b-9) 10 + 2 100 80 A + Fluxapyroxad (b-1) 10 + 2 100 78 A + Benzovindiflupyr (b-2) 10 + 2 97 80 A + Carbendazim (b-59) 10 + 2 100 80 A + Pyribencarb (b-98) 10 + 2 97 80 A + Pyraziflumid (b-49) 10 + 2 97 80 B + Pyriofenone (b-83) 10 + 10 93 78 B + Compound of formula (XV)-1 (b-89) 10 + 2 100 80 B + Oxathiapiprolin (b-84) 10 + 50 100 78 B + Compound of formula (XIX) (b-94) 10 + 0.4 97 80 B + Compound of formula (XVII) (b-91) 10 + 2 100 80 B + Compound of formula (III) (b-8) 10 + 2 100 80 B + Compound of formula (IV) (b-9) 10 + 2 97 80 B + Fluxapyroxad (b-1) 10 + 2 97 78 B + Benzovindiflupyr (b-2) 10 + 2 97 80 B + Carbendazim (b-59) 10 + 2 100 80 B + Pyribencarb (b-98) 10 + 2 100 80 B + Pyraziflumid (b-49) 10 + 2 97 80 C + Pyriofenone (b-83) 10 + 10 100 80 C + Compound of formula (XV)-1 (b-89) 10 + 2 100 82 C + Oxathiapiprolin (b-84) 10 + 50 97 80 C + Compound of formula (XIX) (b-94) 10 + 0.4 100 82 C + Compound of formula (XVII) (b-91) 10 + 2 100 82 C + Compound of formula (III) (b-8) 10 + 2 100 82 C + Compound of formula (IV) (b-9) 10 + 2 100 82 C + Fluxapyroxad (b-1) 10 + 2 100 80 C + Benzovindiflupyr (b-2) 10 + 2 100 82 C + Carbendazim (b-59) 10 + 2 100 82 C + Pyribencarb (b-98) 10 + 2 97 82 C + Pyraziflumid (b-49) 10 + 2 97 82 Pyriofenone (b-83) 10 33 Compound of formula (XV)-1 (b-89) 2 40 Oxathiapiprolin (b-84) 50 33 Compound of formula (XIX) (b-94) 0.4 40 Compound of formula (XVII) (b-91) 2 40 Compound of formula (III) (b-8) 2 40 Compound of formula (IV) (b-9) 2 40 Fluxapyroxad (b-1) 2 33 Benzovindiflupyr (b-2) 2 40 Carbendazim (b-59) 2 40 Pyribencarb (b-98) 2 40 Pyraziflumid (b-49) 2 40 A 10 40 B 10 40 C 10 40

(29) TABLE-US-00011 TABLE 2-9 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Phosphorous acid (b-105) 10 + 250 93 82 A + Propineb (b-69) 10 + 50 93 82 A + Compound of (V) (b-36) 10 + 10 100 84 A + Compound of (XIV) (b-88) 10 + 0.4 97 87 A + Compound of (XI)-1 (b-85) 10 + 10 97 87 A + Compound of (XI)-2 (b-85) 10 + 10 97 87 A + Compound of (XVIII) (b-92) 10 + 0.4 97 87 A + D-tagatose (b-93) 10 + 5000 93 82 B + Phosphorous acid (b-105) 10 + 250 97 82 B + Propineb (b-69) 10 + 50 97 82 B + Compound of (V) (b-36) 10 + 10 100 84 B + Compound of (XIV) (b-88) 10 + 0.4 97 87 B + Compound of (XI)-1 (b-85) 10 + 10 97 87 B + Compound of (XI)-2 (b-85) 10 + 10 97 87 B + Compound of (XVIII) (b-92) 10 + 0.4 97 87 B + D-tagatose (b-93) 10 + 5000 93 82 C + Phosphorous acid (b-105) 10 + 250 93 82 C + Propineb (b-69) 10 + 50 93 82 C + Compound of (V) (b-36) 10 + 10 97 84 C + Compound of (XIV) (b-88) 10 + 0.4 97 87 C + Compound of (XI)-1 (b-85) 10 + 10 97 87 C + Compound of (XI)-2 (b-85) 10 + 10 97 87 C + Compound of (XVIII) (b-92) 10 + 0.4 93 87 C + D-tagatose (b-93) 10 + 5000 93 82 Phosphorous acid (b-105) 250 33 Propineb (b-69) 50 33 Compound of (V) (b-36) 10 40 Compound of (XIV) (b-88) 0.4 50 Compound of (XI)-1 (b-85) 10 50 Compound of (XI)-2 (b-85) 10 50 Compound of (XVIII) (b-92) 0.4 50 D-tagatose (b-93) 5000 33 A 10 73 B 10 73 C 10 73

(30) Based on the results shown in Tables 2-1 to 2-9 above, synergistic effects were determined to be obtained when Compound A, Compound B or Compound C is used in combination with a compound of group b. Furthermore, there were no symptoms of chemical damage observed on the plant bodies or tomatoes (variety: Ohgata Fukuju) even when Compound A, Compound B or Compound C was used in combination with a compound of group b.

Comparative Example 1 Tomato Gray Mold Preventive Test

(31) Wettable powder prepared in compliance with Comparative Preparation Example 4 containing the compounds indicated in Table 2-10 were sprayed to the tomato leaves, a conidia suspension of Botrytis cinerea was inoculated onto the plants, and the controlling effects were examined in a manner similar to Test Example 1. The results and theoretical values as determined according to Colby's formula are shown in Table 2-10.

(32) TABLE-US-00012 TABLE 2-10 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Diclocymet 10 + 50 60 72 A + Carpropamid 10 + 50 67 72 A + Tolclofos-methyl 10 + 50 67 72 A + Oxolinic acid 10 + 50 60 72 B + Diclocymet 10 + 50 67 72 B + Carpropamid 10 + 50 67 72 B + Tolclofos-methyl 10 + 50 60 72 B + Oxolinic acid 10 + 50 60 72 C + Diclocymet 10 + 50 60 72 C + Carpropamid 10 + 50 60 72 C + Tolclofos-methyl 10 + 50 60 72 C + Oxolinic acid 10 + 50 63 72 Diclocymet 50 17 Carpropamid 50 17 Tolclofos-methyl 50 17 Oxolinic acid 50 17 A 10 67 B 10 67 C 10 67

(33) Based on the results shown in Tables 2-10 above, even if these compounds are used in combination with Compound A, Compound B or Compound C, the controlling effects were under their theoretical values and the action resulting from combining two types of active ingredients is indicated to be antagonistic.

Test Example 2 Rice Blast Preventive Test

(34) Rice plants (variety: Sachikaze) planted in plastic pots having a diameter of 5 cm were grown indoors to the third to fourth leaf stage. Wettable powder containing the compounds indicated in Table 3 were sprayed in the same manner as in Test Example 1, and after the chemical had dried, a conidia suspension prepared from Pyricularia oryzae which had been previously cultured in oatmeal medium was inoculated by spraying onto the plants. Following inoculation, the pots were placed in the humidified chamber of an artificial inoculation room (20? C. to 23? C.), and taken out on the next day and then transferred to a greenhouse. Control effects were examined 7 days after inoculation. During the examination, the number of lesions on the rice per pot was determined in accordance with the following incidence degree indicators, and control values and theoretical values as determined according to Colby's formula were calculated in the same manner as in Test Example 1. The results are shown in Tables 3-1 to 3-3.

(35) TABLE-US-00013 Indicator Incidence Degree 0 No lesions 0.5 1 to 2 lesions 1 3 to 5 lesions 2 6 to 10 lesions 3 11 to 20 lesions 4 21 to 30 lesions 5 31 to 40 lesions 6 41 or more lesions or withered

(36) TABLE-US-00014 TABLE 3-1 Treatment concen- Theo- Effective ingredient tration Control retical in the preparation (ppm) value value A + Fluxapyroxad (b-1) 10 + 2 83 72 A + Compound of formula (II) (b-3) 10 + 2 92 72 A + Isofetamid (b-47) 10 + 10 83 72 A + Picarbutrazox (b-78) 10 + 0.4 83 72 A + Pyraziflumid (b-49) 10 + 2 83 72 A + Compound of formula (XIV) (b-88) 10 + 2 92 83 A + Compound of formula (VII)-1 (b-38) 10 + 2 92 83 B + Fluxapyroxad (b-1) 10 + 2 92 72 B + Compound of formula (II) (b-3) 10 + 2 92 72 B + Isofetamid (b-47) 10 + 10 92 72 B + Picarbutrazox (b-78) 10 + 0.4 83 72 B + Pyraziflumid (b-49) 10 + 2 83 72 B + Compound of formula (XIV) (b-88) 10 + 2 100 83 B + Compound of formula (VII)-1 (b-38) 10 + 2 100 83 C + Fluxapyroxad (b-1) 10 + 2 92 72 C + Compound of formula (II) (b-3) 10 + 2 92 72 C + Isofetamid (b-47) 10 + 10 92 72 C + Picarbutrazox (b-78) 10 + 0.4 83 72 C + Pyraziflumid (b-49) 10 + 2 92 72 C + Compound of formula (XIV) (b-88) 10 + 2 100 83 C + Compound of formula (VII)-1 (b-38) 10 + 2 100 83 Fluxapyroxad (b-1) 2 17 Compound of formula (II) (b-3) 2 17 Isofetamid (b-47) 10 17 Picarbutrazox (b-78) 0.4 17 Pyraziflumid (b-49) 2 17 Compound of formula (XIV) (b-88) 2 50 Compound of formula (VII)-1 (b-38) 2 50 A 10 67 B 10 67 C 10 67

(37) TABLE-US-00015 TABLE 3-2 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Fluoxastrobin (b-51) 10 + 10 97 89 A + Dimoxystrobin (b-52) 10 + 10 100 93 A + Orysastrobin (b-53) 10 + 10 100 89 B + Fluoxastrobin (b-51) 10 + 10 100 89 B + Dimoxystrobin (b-52) 10 + 10 100 93 B + Orysastrobin (b-53) 10 + 10 100 89 C + Fluoxastrobin (b-51) 10 + 10 97 89 C + Dimoxystrobin (b-52) 10 + 10 100 93 C + Orysastrobin (b-53) 10 + 10 100 89 Fluoxastrobin (b-51) 10 60 Dimoxystrobin (b-52) 10 73 Orysastrobin (b-53) 10 60 A 10 73 B 10 73 C 10 73

(38) TABLE-US-00016 TABLE 3-3 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Tiadinil (b-45) 10 + 10 100 89 A + Probenazole (b-73) 10 + 10 100 89 A + Tebufloquin (b-64) 10 + 10 100 93 A + Isoprothiolane (b-71) 10 + 50 100 87 A + Pyroquilon (b-104) 10 + 50 100 91 A + Pencycuron (b-76) 10 + 250 93 84 B + Tiadinil (b-45) 10 + 10 100 89 B + Probenazole (b-73) 10 + 10 100 89 B + Tebufloquin (b-64) 10 + 10 100 93 B + Isoprothiolane (b-71) 10 + 50 100 87 B + Pyroquilon (b-104) 10 + 50 97 91 B + Pencycuron (b-76) 10 + 250 100 84 C + Tiadinil (b-45) 10 + 10 100 89 C + Probenazole (b-73) 10 + 10 100 89 C + Tebufloquin (b-64) 10 + 10 100 93 C + Isoprothiolane (b-71) 10 + 50 100 87 C + Pyroquilon (b-104) 10 + 50 97 91 C + Pencycuron (b-76) 10 + 250 97 84 Tiadinil (b-45) 10 60 Probenazole (b-73) 10 60 Tebufloquin (b-64) 10 73 Isoprothiolane (b-71) 50 50 Pyroquilon (b-104) 50 67 Pencycuron (b-76) 250 40 A 10 73 B 10 73 C 10 73

(39) TABLE-US-00017 TABLE 3-4 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Benzovindiflupyr (b-2) 10 + 2 100 80 A + Bixafen (b-4) 10 + 10 97 78 A + Picoxystrobin (b-16) 10 + 2 100 83 A + Trifloxystrobin (b-55) 10 + 2 100 86 A + Pyraclostrobin (b-19) 10 + 2 100 80 A + Fluopyram (b-43) 10 + 10 100 80 A + Prothioconazole (b-23) 10 + 10 100 78 A + Triadimenol (b-33) 10 + 250 97 78 A + Pyrimethanil (b-62) 10 + 50 100 78 A + Isotianil (b-46) 10 + 10 100 83 A + Metominostrobin (b-54) 10 + 2 100 80 A + Acibenzolar-S-methyl (b-72) 10 + 10 100 87 A + Compound of formula (XIX) (b-94) 10 + 0.4 100 83 B + Benzovindiflupyr (b-2) 10 + 2 100 80 B + Bixafen (b-4) 10 + 10 100 78 B + Picoxystrobin (b-16) 10 + 2 100 83 B + Trifloxystrobin (b-55) 10 + 2 100 86 B + Pyraclostrobin (b-19) 10 + 2 100 80 B + Fluopyram (b-43) 10 + 10 100 80 B + Prothioconazole (b-23) 10 + 10 100 78 B + Triadimenol (b-33) 10 + 250 97 78 B + Pyrimethanil (b-62) 10 + 50 97 78 B + Isotianil (b-46) 10 + 10 100 83 B + Metominostrobin (b-54) 10 + 2 100 80 B + Acibenzolar-S-methyl (b-72) 10 + 10 100 87 B + Compound of formula (XIX) (b-94) 10 + 0.4 100 83 C + Benzovindiflupyr (b-2) 10 + 2 100 80 C + Bixafen (b-4) 10 + 10 97 78 C + Picoxystrobin (b-16) 10 + 2 100 83 C + Trifloxystrobin (b-55) 10 + 2 100 86 C + Pyraclostrobin (b-19) 10 + 2 100 80 C + Fluopyram (b-43) 10 + 10 97 80 C + Prothioconazole (b-23) 10 + 10 100 78 C + Triadimenol (b-33) 10 + 250 97 78 C + Pyrimethanil (b-62) 10 + 50 97 78 C + Isotianil (b-46) 10 + 10 100 83 C + Metominostrobin (b-54) 10 + 2 100 80 C + Acibenzolar-S-methyl (b-72) 10 + 10 100 87 C + Compound of formula (XIX) (b-94) 10 + 0.4 97 83 Benzovindiflupyr (b-2) 10 + 2 40 Bixafen (b-4) 10 + 10 33 Picoxystrobin (b-16) 10 + 2 50 Trifloxystrobin (b-55) 10 + 2 57 Pyraclostrobin (b-19) 10 + 2 40 Fluopyram (b-43) 10 + 10 40 Prothioconazole (b-23) 10 + 10 33 Triadimenol (b-33) 10 + 250 33 Pyrimethanil (b-62) 10 + 50 33 Isotianil (b-46) 10 + 10 50 Metominostrobin (b-54) 10 + 2 40 Acibenzolar-S-methyl (b-72) 10 + 10 60 Compound of formula (XIX) (b-94) 10 + 0.4 50 A 10 67 B 10 67 C 10 67

(40) Based on the results shown in Tables 3-1 to 3-4 above, synergistic effects were determined to be obtained when Compound A, Compound B or Compound C is used in combination with a compound of group b. Furthermore, there were no symptoms of chemical damage observed on the plant bodies or rice (variety: Sachikaze) even when Compound A, Compound B or Compound C was used in combination with a compound of group b.

Comparative Example 2 Rice Blast Preventive Test

(41) Wettable powder prepared in compliance with Comparative Preparation Example 4 containing the compounds indicated in Table 3-5 were sprayed to the rice plant leaves, a conidia suspension of Pyricularia oryzae was inoculated onto the plants, and the controlling effects were examined in a manner similar to Test Example 2. The results and theoretical values as determined according to Colby's formula are shown in Table 3-5.

(42) TABLE-US-00018 TABLE 3-5 Treatment concen- Pre- Theo- Effective ingredient tration ventive retical in the preparation (ppm) value value A + Diclocymet 10 + 0.4 83 89 A + Carpropamid 10 + 0.4 77 89 A + Tolclofos-methyl 10 + 10 67 78 A + Oxolinic acid 10 + 50 67 78 B + Diclocymet 10 + 0.4 80 89 B + Carpropamid 10 + 0.4 77 89 B + Tolclofos-methyl 10 + 10 67 78 B + Oxolinic acid 10 + 50 67 78 C + Diclocymet 10 + 0.4 73 89 C + Carpropamid 10 + 0.4 73 89 C + Tolclofos-methyl 10 + 10 67 78 C + Oxolinic acid 10 + 50 67 78 Diclocymet 0.4 67 Carpropamid 0.4 67 Tolclofos-methyl 10 33 Oxolinic acid 50 33 A 10 67 B 10 67 C 10 67

(43) Based on the results shown in Tables 3-5 above, even if these compounds are used in combination with Compound A, Compound B or Compound C, the controlling effects were under their theoretical values and the action resulting from combining two types of active ingredients is indicated to be antagonistic.

Test Example 3 Barley Powdery Mildew Preventive Test

(44) Barley plants (variety: Akashinriki) planted in plastic pots having a diameter of 5 cm were grown indoors to the second to fourth leaf stage. Wettable powder containing the compounds indicated in Table 4 were sprayed in the same manner as in Test Example 1, and after the chemical had dried, conidia of Blumeria graminis was inoculated onto the leaves. Following inoculation, the pots were transferred to a constant-temperature chamber (20? C. to 25? C.), and control effects were examined 8 days after inoculation. During the examination, the percentage of affected area exhibiting lesions on the barley plants per pot was determined in accordance with the following incidence degree indicators, and control values and theoretical values as determined according to Colby's formula were calculated in the same manner as in Test Example 1. The results are shown in Table 4.

(45) TABLE-US-00019 Incidence Degree Indicators Indicator Incidence Degree 0 No lesions 0.5 Lesion area of about 1% to 2% 1 Lesion area of less than 5% 2 Lesion area of less than 25% 3 Lesion area of less than 50% 4 Lesion area of less than 75% 5 Lesion area of 75% or more

(46) TABLE-US-00020 TABLE 4 Treatment concen- Theo- Effective ingredient tration Control retical in the preparation (ppm) value value A + Fluxapyroxad (b-1) 10 + 2 67 63 A + Benzovindiflupyr (b-2) 10 + 2 56 53 A + Compound of formula (II) (b-3) 10 + 2 78 69 A + Isofetamid (b-47) 10 + 10 86 69 A + Compound of formula (XIV) (b-88) 10 + 2 72 58 A + Compound of formula (VII)-1 (b-38) 10 + 2 97 82 B + Fluxapyroxad (b-1) 10 + 2 67 63 B + Benzovindiflupyr (b-2) 10 + 2 67 53 B + Compound of formula (II) (b-3) 10 + 2 72 69 B + Isofetamid (b-47) 10 + 10 83 69 B + Compound of formula (XIV) (b-88) 10 + 2 61 58 B + Compound of formula (VII)-1 (b-38) 10 + 2 89 82 C + Fluxapyroxad (b-1) 10 + 2 86 63 C + Benzovindiflupyr (b-2) 10 + 2 72 53 C + Compound of formula (II) (b-3) 10 + 2 78 69 C + Isofetamid (b-47) 10 + 10 92 69 C + Compound of formula (XIV) (b-88) 10 + 2 61 58 C + Compound of formula (VII)-1 (b-38) 10 + 2 83 82 Fluxapyroxad (b-1) 2 61 Benzovindiflupyr (b-2) 2 50 Compound of formula (II) (b-3) 2 67 Isofetamid (b-47) 10 67 Compound of formula (XIV) (b-88) 2 56 Compound of formula (VII)-1 (b-38) 2 81 A 10 6 B 10 6 C 10 6

(47) Based on the results shown in Table 4 above, synergistic effects were determined to be obtained when Compound A, Compound B or Compound C is used in combination with a compound of group b. Furthermore, there were no symptoms of chemical damage observed on the plant bodies or barley (variety: Akashinriki) even when Compound A, Compound B or Compound C was used in combination with a compound of group b.

Test Example 4 Wheat Brown Rust Preventive Test

(48) Wheat plants (variety: Norin 61 gou) planted in plastic pots having a diameter of 5 cm were grown indoors to the second to fourth leaf stage. Wettable powder containing the compounds indicated in Table 5 were sprayed in the same manner as in Test Example 1, and after the chemical had dried, a conidia suspension of Puccinia recondita was inoculated onto the leaves. Following inoculation, the pots were placed in the humidified chamber of an artificial inoculation room (20? C. to 23? C.), removed on the following day and then transferred to a greenhouse. Control effects were examined 8 days after inoculation. During the examination, the number of lesions on five leaves of the wheat plants was determined in accordance with the following incidence degree indicators, and control values and theoretical values as determined according to Colby's formula were calculated in the same manner as in Test Example 1. The results are shown in Table 5.

(49) TABLE-US-00021 Indicator Incidence Degree 0 No lesions 0.5 1 to 2 lesions 1 3 to 5 lesions 2 6 to 20 lesions 3 21 to 50 lesions 4 51 to 80 lesions 5 81 to 100 lesions 6 101 or more lesions

(50) TABLE-US-00022 TABLE 5 Treatment Effective ingredient concentration Theoretical in the preparation (ppm) Control value value A + Fluxapyroxad (b-1) 10 + 2 89 75 A + Isofetamid (b-47) 10 + 10 22 14 A + Picarbutrazox 10 + 0.4 22 14 (b-78) A + Pyraziflumid 10 + 2 92 86 (b-49) A + Compound of 10 + 2 53 48 formula (XIV) (b-88) A + Compound of 10 + 2 82 73 formula (VII)-1 (b-38) B + Fluxapyroxad (b-1) 10 + 2 86 74 B + Isofetamid (b-47) 10 + 10 53 8 B + Picarbutrazox 10 + 0.4 53 8 (b-78) B + Pyraziflumid 10 + 2 94 86 (b-49) B + Compound of 10 + 2 72 45 formula (XIV) (b-88) B + Compound of 10 + 2 90 71 formula (VII)-1 (b-38) C + Fluxapyroxad (b-1) 10 + 2 90 75 C + Isofetamid (b-47) 10 + 10 47 11 C + Picarbutrazox 10 + 0.4 50 11 (b-78) C + Pyraziflumid 10 + 2 92 86 (b-49) C + Compound of 10 + 2 64 47 formula (XIV) (b-88) C + Compound of 10 + 2 78 72 formula (VII)-1 (b-38) Fluxapyroxad (b-1) 2 72 Isofetamid (b-47) 10 3 Picarbutrazox 0.4 3 (b-78) Pyraziflumid 2 85 (b-49) Compound of 2 42 formula (XIV) (b-88) Compound of 2 69 formula (VII)-1 (b-38) A 10 11 B 10 6 C 10 8

(51) Based on the results shown in Table 5 above, synergistic effects were determined to be obtained when Compound A, Compound B or Compound C is used in combination with a compound of group b. Furthermore, there were no symptoms of chemical damage observed on the plant bodies or wheat (variety: Norin No. 61) even when Compound A, Compound B or Compound C was used in combination with a compound of group b.

Test Example 5 Tomato Late Blight Preventive Test

(52) Tomato plants (variety: Ohgata Fukuju) planted in plastic pots having a diameter of 5 cm were grown indoors to the second to third leaf stage. Wettable powders containing the compounds indicated in Table 6 were sprayed in the same manner as in Test Example 1, and after the chemical had dried, a zoospores and zoosporangium suspension of Phytophthora infestans was inoculated by spraying onto the plants. Following inoculation, the pots were placed in the humidified chamber of an artificial inoculation room (20? C. to 22? C.) and then transferred to a greenhouse on the following day followed by examining control effects 5 days after inoculation. The percentage of affected area exhibiting lesions on a single tomato leaf was determined in accordance with the same indicators as used in Test Example 1, and control values and theoretical values as determined according to Colby's formula were calculated in the same manner as in Test Example 1. The results are shown in Tables 6-1 to 6-2.

(53) TABLE-US-00023 TABLE 6-1 Effective ingredient Treatment Theoretical in the preparation concentration (ppm) Control value value A + Picarbutrazox 10 + 0.4 96 77 (b-78) B + Picarbutrazox 10 + 0.4 96 78 (b-78) C + Picarbutrazox 10 + 0.4 94 76 (b-78) Picarbutrazox 0.4 75 (b-78) A 10 8 B 10 13 C 10 4

(54) TABLE-US-00024 TABLE 6-2 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Mandipropamid (b-44) 10 + 0.08 97 78 A + Fluopicolide (b-40) 10 + 2 97 60 A + Benalaxyl-M (b-75) 10 + 2 87 60 A + Iprovalicarb (b-50) 10 + 2 90 67 A + Amisulbrom (b-97) 10 + 0.08 83 67 A + Ametoctradin (b-95) 10 + 2 87 60 A + Zoxamide (b-39) 10 + 0.4 83 60 A + Hymexazol (b-106) 10 + 250 73 56 B + Mandipropamid (b-44) 10 + 0.08 93 78 B + Fluopicolide (b-40) 10 + 2 87 60 B + Benalaxyl-M (b-75) 10 + 2 90 60 B + Iprovalicarb (b-50) 10 + 2 90 67 B + Amisulbrom (b-97) 10 + 0.08 87 67 B + Ametoctradin (b-95) 10 + 2 83 60 B + Zoxamide (b-39) 10 + 0.4 87 60 B + Hymexazol (b-106) 10 + 250 73 56 C + Mandipropamid (b-44) 10 + 0.08 97 80 C + Fluopicolide (b-40) 10 + 2 93 64 C + Benalaxyl-M (b-75) 10 + 2 90 64 C + Iprovalicarb (b-50) 10 + 2 90 70 C + Amisulbrom (b-97) 10 + 0.08 90 70 C + Ametoctradin (b-95) 10 + 2 90 64 C + Zoxamide (b-39) 10 + 0.4 87 64 C + Hymexazol (b-106) 10 + 250 83 60 Mandipropamid (b-44) 0.08 67 Fluopicolide (b-40) 2 40 Benalaxyl-M (b-75) 2 40 Iprovalicarb (b-50) 2 50 Amisulbrom (b-97) 0.08 50 Ametoctradin (b-95) 2 40 Zoxamide (b-39) 0.4 40 Hymexazol (b-106) 250 33 A 10 33 B 10 33 C 10 40

(55) TABLE-US-00025 TABLE 6-3 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Oxathiapiprolin (b-84) 10 + 0.0016 100 82 A + Dithianon (b-81) 10 + 2 87 64 A + D-tagatose (b-93) 10 + 5000 90 68 B + Oxathiapiprolin (b-84) 10 + 0.0016 100 80 B + Dithianon (b-81) 10 + 2 87 60 B + D-tagatose (b-93) 10 + 5000 93 64 C + Oxathiapiprolin (b-84) 10 + 0.0016 100 79 C + Dithianon (b-81) 10 + 2 87 58 C + D-tagatose (b-93) 10 + 5000 90 62 Oxathiapiprolin (b-84) 0.0016 67 Dithianon (b-81) 2 33 D-tagatose (b-93) 5000 40 A 10 47 B 10 40 C 10 37

(56) Based on the results shown in Tables 6-1 and 6-3 above, synergistic effects were determined to be obtained when Compound A, Compound B or Compound C is used in combination with a compound of group b. Furthermore, there were no symptoms of chemical damage observed on the plant bodies or tomatoes (variety: Ohgata Fukuju) even when Compound A, Compound B or Compound C was used in combination with a compound of group b.

Test Example 6 Cucumber Powdery Mildew Preventive Test

(57) In a greenhouse, cucumber (variety: Sagamihanshiro) planted in a plastic pot having a diameter of 5 cm was grown to the 3rd to 5th-leaf stage. Spray was carried out in the same manner as in Test example 1, and 3 days after the spray, a conidia suspension prepared from Sphaerotheca fuliginea were inoculated on the leaf surface. After inoculation, the pots were placed in a thermostatic greenhouse (20 to 25? C.), and controlling effects were examined after 7 days from the inoculation. In the examination, a ratio of lesion area occupied per one leaf of cucumber was determined according to the same index as in Test example 1, and the control value and the theoretical value according to Colby's formula were similarly calculated. The results are shown in Table 7-1 to 7-8

(58) TABLE-US-00026 TABLE 7-1 Treatment Effective ingredient in the concentration Theoretical preparation (ppm) Control value value A + Fluoxastrobin (b-51) 10 + 2 93 73 A + Dimoxystrobin (b-52) 10 + 2 93 73 A + Orysastrobin (b-53) 10 + 2 97 60 B + Fluoxastrobin (b-51) 10 + 2 87 73 B + Dimoxystrobin (b-52) 10 + 2 93 73 B + Orysastrobin (b-53) 10 + 2 90 60 C + Fluoxastrobin (b-51) 10 + 2 97 73 C + Dimoxystrobin (b-52) 10 + 2 93 73 C + Orysastrobin (b-53) 10 + 2 97 60 Fluoxastrobin (b-51) 2 60 Dimoxystrobin (b-52) 2 60 Orysastrobin (b-53) 2 40 A 10 33 B 10 33 C 10 33

(59) TABLE-US-00027 TABLE 7-2 Treatment Effective ingredient in the concentration Control Theoretical preparation (ppm) value value A + Carboxin (b-41) 10 + 50 87 50 A + Thifluzamide (b-42) 10 + 50 100 78 A + Isopyrazam (b-7) 10 + 0.4 87 50 A + Sedaxane (b-6) 10 + 0.4 87 50 A + Penflufen (b-5) 10 + 2 100 78 A + Cyprodinil (b-61) 10 + 10 87 50 A + Fenpyrazamine (b-99) 10 + 50 87 44 B + Carboxin (b-41) 10 + 50 87 50 B + Thifluzamide (b-42) 10 + 50 100 78 B + Isopyrazam (b-7) 10 + 0.4 87 50 B + Sedaxane (b-6) 10 + 0.4 87 50 B + Penflufen (b-5) 10 + 2 100 78 B + Cyprodinil (b-61) 10 + 10 87 50 B + Fenpyrazamine (b-99) 10 + 50 87 44 C + Carboxin (b-41) 10 + 50 87 50 C + Thifluzamide (b-42) 10 + 50 100 78 C + Isopyrazam (b-7) 10 + 0.4 93 50 C + Sedaxane (b-6) 10 + 0.4 90 50 C + Penflufen (b-5) 10 + 2 100 78 C + Cyprodinil (b-61) 10 + 10 87 50 C + Fenpyrazamine (b-99) 10 + 50 87 44 Carboxin (b-41) 50 40 Thifluzamide (b-42) 50 73 Isopyrazam (b-7) 0.4 40 Sedaxane (b-6) 0.4 40 Penflufen (b-5) 2 73 Cyprodinil (b-61) 10 40 Fenpyrazamine (b-99) 50 33 A 10 17 B 10 17 C 10 17

(60) TABLE-US-00028 TABLE 7-3 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Tetraconazole (b-22) 10 + 0.4 83 70 A + Epoxiconazole (b-24) 10 + 0.4 90 64 A + Ipconazole (b-25) 10 + 0.4 93 70 A + Metconazole (b-26) 10 + 0.4 90 70 A + Propiconazole (b-27) 10 + 0.4 93 64 A + Cyproconazole (b-28) 10 + 0.4 87 64 A + Difenoconazole (b-29) 10 + 0.4 90 70 A + Fluquinconazole (b-30) 10 + 0.4 90 70 A + Flusilazole (b-31) 10 + 0.4 87 64 A + Penconazole(b-32) 10 + 0.4 87 68 A + Flutriafol (b-34) 10 + 0.4 90 64 A + Myclobutanil (b-35) 10 + 0.4 93 68 A + Imazalil (b-20) 10 + 0.4 90 60 A + Prochloraz(b-21) 10 + 0.4 87 68 B + Tetraconazole (b-22) 10 + 0.4 87 67 B + Epoxiconazole (b-24) 10 + 0.4 83 60 B + Ipconazole (b-25) 10 + 0.4 87 67 B + Metconazole (b-26) 10 + 0.4 90 67 B + Propiconazole (b-27) 10 + 0.4 87 60 B + Cyproconazole (b-28) 10 + 0.4 83 64 B + Difenoconazole (b-29) 10 + 0.4 87 60 B + Fluquinconazole (b-30) 10 + 0.4 90 64 B + Flusilazole (b-31) 10 + 0.4 87 56 B + Penconazole(b-32) 10 + 0.4 90 64 B + Flutriafol (b-34) 10 + 0.4 87 60 B + Myclobutanil (b-35) 10 + 0.4 80 56 B + Imazalil (b-20) 10 + 0.4 83 60 B + Prochloraz(b-21) 10 + 0.4 87 67 C + Tetraconazole (b-22) 10 + 0.4 90 67 C + Epoxiconazole (b-24) 10 + 0.4 93 60 C + Ipconazole (b-25) 10 + 0.4 90 67 C + Metconazole (b-26) 10 + 0.4 90 67 C + Propiconazole (b-27) 10 + 0.4 90 60 C + Cyproconazole (b-28) 10 + 0.4 87 64 C + Difenoconazole (b-29) 10 + 0.4 90 60 C + Fluquinconazole (b-30) 10 + 0.4 87 64 C + Flusilazole (b-31) 10 + 0.4 90 56 C + Penconazole(b-32) 10 + 0.4 87 64 C + Flutriafol (b-34) 10 + 0.4 83 60 C + Myclobutanil (b-35) 10 + 0.4 87 56 C + Imazalil (b-20) 10 + 0.4 90 60 C + Prochloraz(b-21) 10 + 0.4 87 67 Tetraconazole (b-22) 0.4 50 Epoxiconazole (b-24) 0.4 40 Ipconazole (b-25) 0.4 50 Metconazole (b-26) 0.4 50 Propiconazole (b-27) 0.4 40 Cyproconazole (b-28) 0.4 47 Difenoconazole (b-29) 0.4 40 Fluquinconazole (b-30) 0.4 47 Flusilazole (b-31) 0.4 33 Penconazole(b-32) 0.4 47 Flutriafol (b-34) 0.4 40 Myclobutanil (b-35) 0.4 33 Imazalil (b-20) 0.4 40 Prochloraz(b-21) 0.4 50 A 10 40 B 10 33 C 10 33

(61) TABLE-US-00029 TABLE 7-4 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Thiabendazole (b-60) 10 + 10 90 64 A + Benomyl (b-58) 10 + 10 97 70 A + Thiuram (b-68) 10 + 50 87 60 A + Metiram (b-67) 10 + 50 87 60 A + Folpet (b-70) 10 + 50 80 60 A + Pyrisoxazole (b-103) 10 + 50 90 60 B + Thiabendazole (b-60) 10 + 10 97 64 B + Benomyl (b-58) 10 + 10 93 70 B + Thiuram (b-68) 10 + 50 80 60 B + Metiram (b-67) 10 + 50 80 60 B + Folpet (b-70) 10 + 50 77 60 B + Pyrisoxazole (b-103) 10 + 50 97 60 C + Thiabendazole (b-60) 10 + 10 97 64 C + Benomyl (b-58) 10 + 10 97 70 C + Thiuram (b-68) 10 + 50 83 60 C + Metiram (b-67) 10 + 50 80 60 C + Folpet (b-70) 10 + 50 80 60 C + Pyrisoxazole (b-103) 10 + 50 90 60 Thiabendazole (b-60) 10 40 Benomyl (b-58) 10 50 Thiuram (b-68) 50 33 Metiram (b-67) 50 33 Folpet (b-70) 50 33 Pyrisoxazole (b-103) 50 33 A 10 40 B 10 40 C 10 40

(62) TABLE-US-00030 TABLE 7-5 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Fenpropimorph (b-65) 10 + 0.4 80 60 A + Tridemorph (b-66) 10 + 0.4 80 60 A + Metrafenone (b-82) 10 + 0.08 83 64 A + Quinoxyfen (b-63) 10 + 0.016 97 76 A + Flutianil (b-77) 10 + 0.016 97 80 A + Proquinazid (b-100) 10 + 0.016 97 64 A + Spiroxamine (b-101) 10 + 0.4 83 60 A + Fenpropidin (b-102) 10 + 0.4 97 64 A + Sulfur (b-96) 10 + 10 100 84 A + Chinomethionat (b-74) 10 + 0.4 83 70 B + Fenpropimorph (b-65) 10 + 0.4 80 60 B + Tridemorph (b-66) 10 + 0.4 80 60 B + Metrafenone (b-82) 10 + 0.08 83 64 B + Quinoxyfen (b-63) 10 + 0.016 83 76 B + Flutianil (b-77) 10 + 0.016 97 80 B + Proquinazid (b-100) 10 + 0.016 97 64 B + Spiroxamine (b-101) 10 + 0.4 87 60 B + Fenpropidin (b-102) 10 + 0.4 80 64 B + Sulfur (b-96) 10 + 10 97 84 B + Chinomethionat (b-74) 10 + 0.4 83 70 C + Fenpropimorph (b-65) 10 + 0.4 83 60 C + Tridemorph (b-66) 10 + 0.4 83 60 C + Metrafenone (b-82) 10 + 0.08 93 64 C + Quinoxyfen (b-63) 10 + 0.016 97 76 C + Flutianil (b-77) 10 + 0.016 97 80 C + Proquinazid (b-100) 10 + 0.016 97 64 C + Spiroxamine (b-101) 10 + 0.4 87 60 C + Fenpropidin (b-102) 10 + 0.4 80 64 C + Sulfur (b-96) 10 + 10 97 84 C + Chinomethionat (b-74) 10 + 0.4 80 70 Fenpropimorph (b-65) 0.4 33 Tridemorph (b-66) 0.4 33 Metrafenone (b-82) 0.08 40 Quinoxyfen (b-63) 0.016 60 Flutianil (b-77) 0.016 67 Proquinazid (b-100) 0.016 40 Spiroxamine (b-101) 0.4 33 Fenpropidin (b-102) 0.4 40 Sulfur (b-96) 10 73 Chinomethionat (b-74) 0.4 50 A 10 40 B 10 40 C 10 40

(63) TABLE-US-00031 TABLE 7-6 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Tiadinil (b-45) 10 + 10 87 64 A + Probenazole (b-73) 10 + 10 93 64 A + Tebufloquin (b-64) 10 + 10 90 80 A + Isoprothiolane (b-71) 10 + 10 83 64 A + Pyroquilon (b-104) 10 + 50 83 44 A + Pencycuron (b-76) 10 + 250 80 60 B + Tiadinil (b-45) 10 + 10 83 64 B + Probenazole (b-73) 10 + 10 87 64 B + Tebufloquin (b-64) 10 + 10 93 80 B + Isoprothiolane (b-71) 10 + 10 80 64 B + Pyroquilon (b-104) 10 + 50 80 44 B + Pencycuron (b-76) 10 + 250 80 60 C + Tiadinil (b-45) 10 + 10 93 64 C + Probenazole (b-73) 10 + 10 90 64 C + Tebufloquin (b-64) 10 + 10 87 80 C + Isoprothiolane (b-71) 10 + 10 80 64 C + Pyroquilon (b-104) 10 + 50 80 44 C + Pencycuron (b-76) 10 + 250 77 60 Tiadinil (b-45) 10 40 Probenazole (b-73) 10 40 Tebufloquin (b-64) 10 67 Isoprothiolane (b-71) 10 40 Pyroquilon (b-104) 50 7 Pencycuron (b-76) 250 33 A 10 40 B 10 40 C 10 40

(64) TABLE-US-00032 TABLE 7-7 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Pyriofenone (b-83) 10 + 0.08 93 64 A + Compound of 10 + 2 93 64 formula (XV)-1 (b-89) A + Oxathiapiprolin (b-84) 10 + 50 87 50 A + Compound of 10 + 10 93 70 formula (XIX) (b-94) A + Compound of 10 + 0.08 97 64 formula (XVII) (b-91) A + Compound of 10 + 0.4 97 76 formula (III) (b-8) A + Compound of 10 + 0.4 97 76 formula (IV) (b-9) A + Isotianil(b-46) 10 + 2 90 60 A + Acibenzolar-S-methyl (b-72) 10 + 2 90 60 B + Pyriofenone (b-83) 10 + 0.08 93 64 B + Compound of 10 + 2 93 64 formula (XV)-1 (b-89) B + Oxathiapiprolin (b-84) 10 + 50 87 50 B + Compound of 10 + 10 93 70 formula (XIX) (b-94) B + Compound of 10 + 0.08 97 64 formula (XVII) (b-91) B + Compound of 10 + 0.4 100 76 formula (III) (b-8) B + Compound of 10 + 0.4 97 76 formula (IV) (b-9) B + Isotianil(b-46) 10 + 2 93 60 B + Acibenzolar-S-methyl (b-72) 10 + 2 93 60 C + Pyriofenone (b-83) 10 + 0.08 93 64 C + Compound of 10 + 2 90 64 formula (XV)-1 (b-89) C + Oxathiapiprolin (b-84) 10 + 50 87 50 C + Compound of 10 + 10 93 70 formula (XIX) (b-94) C + Compound of 10 + 0.08 97 64 formula (XVII) (b-91) C + Compound of 10 + 0.4 97 76 formula (III) (b-8) C + Compound of 10 + 0.4 97 76 formula (IV) (b-9) C + Isotianil(b-46) 10 + 2 90 60 C + Acibenzolar-S-methyl (b-72) 10 + 2 90 60 Pyriofenone (b-83) 0.08 40 Compound of 2 40 formula (XV)-1 (b-89) Oxathiapiprolin (b-84) 50 17 Compound of 10 50 formula (XIX) (b-94) Compound of 0.08 40 formula (XVII) (b-91) Compound of 0.4 60 formula (III) (b-8) Compound of 0.4 60 formula (IV) (b-9) Isotianil(b-46) 2 33 Acibenzolar-S-methyl (b-72) 2 33 A 10 40 B 10 40 C 10 40

(65) TABLE-US-00033 TABLE 7-8 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Phosphorous acid (b-105) 10 + 50 93 60 A + Propineb (b-69) 10 + 50 97 50 A + Compound of (V) (b-36) 10 + 0.4 90 60 A + Compound of (XIV) (b-88) 10 + 0.4 93 64 A + Compound of 10 + 10 97 70 (XI)-1 (b-85) A + Compound of 10 + 10 93 70 (XI)-2 (b-85) A + Compound of 10 + 0.4 90 64 (XVIII) (b-92) A + D-tagatose (b-93) 10 + 5000 93 60 B + Phosphorous acid (b-105) 10 + 50 90 60 B + Propineb (b-69) 10 + 50 97 50 B + Compound of (V) (b-36) 10 + 0.4 93 60 B + Compound of (XIV) (b-88) 10 + 0.4 93 64 B + Compound of 10 + 10 93 70 (XI)-1 (b-85) B + Compound of 10 + 10 97 70 (XI)-2 (b-85) B + Compound of 10 + 0.4 97 64 (XVIII) (b-92) B + D-tagatose (b-93) 10 + 5000 93 60 C + Phosphorous acid (b-105) 10 + 50 90 60 C + Propineb (b-69) 10 + 50 97 50 C + Compound of (V) (b-36) 10 + 0.4 93 60 C + Compound of (XIV) (b-88) 10 + 0.4 97 64 C + Compound of 10 + 10 90 70 (XI)-1 (b-85) C + Compound of 10 + 10 90 70 (XI)-2 (b-85) C + Compound of 10 + 0.4 93 64 (XVIII) (b-92) C + D-tagatose (b-93) 10 + 5000 93 60 Phosphorous acid (b-105) 50 33 Propineb (b-69) 50 17 Compound of 0.4 33 (V) (b-36) Compound of 0.4 40 (XIV) (b-88) Compound of 10 50 (XI)-1 (b-85) Compound of 10 50 (XI)-2 (b-85) Compound of 0.4 40 (XVIII) (b-92) D-tagatose (b-93) 5000 33 A 10 40 B 10 40 C 10 40

(66) From the results shown in the above-mentioned Table 7-1 to 7-8, it could be understood that synergistic effects could be obtained when Compound A, B or C and the compound of Group b are used in combination. Incidentally, even when Compound A, B or C and the compound of Group b are used in combination, no chemical damage symptom was admitted in the plant material, cucumber (variety: Sagamihanpaku).

Comparative Example 3 Cucumber Powdery Mildew Preventive Test

(67) Wettable powder prepared in compliance with Comparative Preparation Example 4 containing the compounds indicated in Table 7-9 were sprayed to the cucumber leaves, a conidiospore suspension prepared from Sphaerotheca fuliginea was inoculated onto the plants, and the controlling effects were examined in a manner similar to Test Example 6. The results and theoretical values as determined according to Colby's formula are shown in Table 7-9.

(68) TABLE-US-00034 TABLE 7-9 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Diclocymet 10 + 50 50 60 A + Carpropamid 10 + 50 47 64 A + Tolclofos-methyl 10 + 50 40 60 A + Oxolinic acid 10 + 50 40 60 B + Diclocymet 10 + 50 40 60 B + Carpropamid 10 + 50 40 64 B + Tolclofos-methyl 10 + 50 40 60 B + Oxolinic acid 10 + 50 40 60 C + Diclocymet 10 + 50 40 60 C + Carpropamid 10 + 50 40 64 C + Tolclofos-methyl 10 + 50 33 60 C + Oxolinic acid 10 + 50 33 60 Diclocymet 50 40 Carpropamid 50 33 Tolclofos-methyl 50 33 Oxolinic acid 50 33 A 10 40 B 10 40 C 10 40

(69) Based on the results shown in Tables 7-9 above, even if these compounds are used in combination with Compound A, Compound B or Compound C, the controlling effects were under their theoretical values and the action resulting from combining two types of active ingredients is indicated to be antagonistic.

Test Example 7 Cucumber Downy Mildew Preventive Test

(70) In a greenhouse, cucumber (variety: Sagamihanshiro) planted in a plastic pot having a diameter of 5 cm was grown to the 3rd to 5th-leaf stage. Spray was carried out in the same manner as in Test example 1, and after drying the chemical liquid, the pots were transferred into a greenhouse. After 3 days from the spray, a zoosporangium suspension of Pseudoperonospora cubensis was inoculated. After inoculation, the pots were placed in a high-humidity chamber (20 to 25? C.), transferred into a greenhouse on the next day, and controlling effects were examined after 7 days from the inoculation. A ratio of lesion area occupied per one leaf of cucumber was determined according to the same index as in Test example 1, and the control value and the theoretical value according to Colby's formula were similarly calculated. The results are shown in Tables 8.

(71) TABLE-US-00035 TABLE 8 Treatment Effective ingredient concentration Preventive Theoretical in the preparation (ppm) value value A + Mandipropamid (b-44) 10 + 0.08 100 76 A + Fluopicolide (b-40) 10 + 2 97 76 A + Benalaxyl-M (b-75) 10 + 2 100 76 A + Iprovalicarb (b-50) 10 + 2 93 63 A + Amisulbrom (b-97) 10 + 0.08 93 76 A + Ametoctradin (b-95) 10 + 2 93 63 A + Zoxamide (b-39) 10 + 0.4 93 51 A + Hymexazol (b-106) 10 + 250 93 39 B + Mandipropamid (b-44) 10 + 0.08 97 74 B + Fluopicolide (b-40) 10 + 2 93 74 B + Benalaxyl-M (b-75) 10 + 2 97 74 B + Iprovalicarb (b-50) 10 + 2 93 62 B + Amisulbrom (b-97) 10 + 0.08 93 74 B + Ametoctradin (b-95) 10 + 2 97 62 B + Zoxamide (b-39) 10 + 0.4 93 49 B + Hymexazol (b-106) 10 + 250 93 36 C + Mandipropamid (b-44) 10 + 0.08 93 72 C + Fluopicolide (b-40) 10 + 2 90 72 C + Benalaxyl-M (b-75) 10 + 2 90 72 C + Iprovalicarb (b-50) 10 + 2 93 58 C + Amisulbrom (b-97) 10 + 0.08 97 72 C + Ametoctradin (b-95) 10 + 2 97 58 C + Zoxamide (b-39) 10 + 0.4 97 44 C + Hymexazol (b-106) 10 + 250 87 31 Mandipropamid (b-44) 0.08 67 Fluopicolide (b-40) 2 67 Benalaxyl-M (b-75) 2 67 Iproyalicarb (b-50) 2 50 Amisulbrom (b-97) 0.08 67 Ametoctradin (b-95) 2 50 Zoxamide (b-39) 0.4 33 Hymexazol (b-106) 250 17 A 10 27 B 10 23 C 10 17

(72) From the results of the above-mentioned Tables 8, it could be understood that synergistic effects could be obtained when Compound A, B or C and the compound of Group b are used in combination. Incidentally, even when Compound A, B or C and the compound of Group b are used in combination, no chemical damage symptom was admitted in the plant material, cucumber (variety: Sagamihanpaku).

INDUSTRIAL APPLICABILITY

(73) The plant disease control composition of the present invention is used as a superior plant disease control agent since it has a plurality of disease spectra against various plant pathogens, including fungicide-resistant organisms (such as Pyricularia oryzae that causes rice blast or Botrytis cinerea that causes gray mold in tomatoes, cucumbers and green beans), exhibits superior control effects (synergistic control effects) that cannot be predicted from the individual components alone, demonstrates a high level of plant disease control effects even against organisms resistant to existing chemical agents, and is observed to be free of the occurrence of phytotoxicity.